QuidelOrtho (QDEL) EVP Siegrist has 2,448 RSUs vest and updates holdings

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported equity compensation activity involving restricted stock units and common shares. On January 29, 2026, 2,448 restricted stock units vested and converted into the same number of QuidelOrtho common shares at $0 per share.

To cover tax withholding on this vesting, 1,009 common shares were disposed of at a price of $27.41 per share through share withholding. After these transactions, Siegrist directly owned 13,419 common shares and held 4,898 restricted stock units, which are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.

Insider Trade Summary

2,448 shares exercised/converted

Mixed 3 txns

Insider Siegrist Jonathan Philip

Role EVP of R&D & CTO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,448	$0.00	--
Grant/Award	Common Stock	2,448	$0.00	--
Tax Withholding	Common Stock	1,009	$27.41	$28K

Holdings After Transaction: Restricted Stock Units — 4,898 shares (Direct); Common Stock — 14,428 shares (Direct)

Footnotes (1)

Reflects release of restricted stock units that were previously reported on a Form 4. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. 2,448 shares vested on January 29, 2026; the remaining 4,898 shares will vest in equal installments on January 29, 2027 and January 29, 2028.

Form 4 Insider Transactions: What Each Field Means →

02/02/2026 - 07:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siegrist Jonathan Philip

(Last)

(First)

(Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP of R&D & CTO

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/29/2026		A		2,448⁽¹⁾	A	$0	14,428	D
Common Stock	01/29/2026		F		1,009⁽²⁾	D	$27.41	13,419	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽³⁾	01/29/2026		M			2,448	⁽⁴⁾	⁽⁴⁾	Common Stock	2,448	$0	4,898	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 4.

2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.

3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

4. 2,448 shares vested on January 29, 2026; the remaining 4,898 shares will vest in equal installments on January 29, 2027 and January 29, 2028.

Remarks:

	/s/ Jennifer Ahn, attorney-in-fact for Jonathan P. Siegrist	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did QuidelOrtho (QDEL) report for Jonathan Siegrist?

QuidelOrtho reported that EVP of R&D & CTO Jonathan Philip Siegrist had 2,448 restricted stock units vest into common shares. In connection with this vesting, shares were withheld to satisfy tax obligations and his post-transaction holdings were updated.

How many QuidelOrtho (QDEL) restricted stock units vested in this Form 4?

A total of 2,448 restricted stock units vested for Jonathan Philip Siegrist on January 29, 2026. Each unit represents the right to receive one share of QuidelOrtho common stock, so 2,448 new common shares were issued to him at no cash cost.

Why were 1,009 QuidelOrtho (QDEL) shares disposed of in this filing?

The 1,009 shares were disposed of to cover tax withholding related to the restricted stock unit vesting. The issuer withheld these common shares at a price of $27.41 per share to satisfy Siegrist’s tax obligations arising from the release of the units.

How many QuidelOrtho (QDEL) shares does Jonathan Siegrist own after the reported transactions?

After the January 29, 2026 transactions, Jonathan Philip Siegrist directly owned 13,419 shares of QuidelOrtho common stock. This figure reflects both the shares received from vesting and the shares withheld to cover related tax obligations described in the Form 4.

What QuidelOrtho (QDEL) equity awards remain unvested for Jonathan Siegrist?

Following the vesting event, Jonathan Philip Siegrist held 4,898 remaining restricted stock units. According to the disclosure, these units are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028, subject to applicable award terms.

What role does Jonathan Siegrist hold at QuidelOrtho (QDEL) in this Form 4?

In this filing, Jonathan Philip Siegrist is identified as an officer of QuidelOrtho, serving as Executive Vice President of Research & Development and Chief Technology Officer. The Form 4 reports his personal equity compensation activity as a company executive.